Fig. 5From: The therapeutic HIV Env C5/gp41 vaccine candidate Vacc-C5 induces specific T cell regulation in a phase I/II clinical studyVacc-C5-specific proliferative T cell responses without and with blockade of IL-10 and TGF-β in CD8+ (upper panel) and CD4+ (lower panel) T cell subsets at week 1 (baseline) (left panel) and week 26 (end of study) (right panel). Significant differences are indicated (Wilcoxon matched pairs test)Back to article page